Abbott Laboratories
Search results
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [2] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection.
AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives.
May 7, 2024 · Science and innovation are the lifeblood of our company. From drug discovery to clinical trials to regulatory approval, we're pursuing new ways to address patients' most challenging health issues. Since our launch in 2013, we've invested more than $63 billion in R&D.
Search for information or submit an inquiry to the AbbVie Medical Information team. Begin your search by selecting a product, after which you may select from relevant categories. If you are unable to find documents with the search tool, please fill out the ‘submit inquiry’ form below.
Answers to questions concerning AbbVie stock purchase, dividends, and how to contact AbbVie's transfer agent and Investor Relations.
AbbVie formed a new kind of enterprise – a biopharmaceutical company – with the stability, global scale, resources and commercial capabilities of a pharmaceutical company and the focus and culture of a biotech. Since the beginning, our mission hasn't wavered.
5 days ago · Our media library provides you with our official AbbVie media including our logo, building and leaders.
Apr 18, 2022 · AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
